BioPharmSignal logoBioPharmSignal

Biotech News

Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Humacyte (HUMA)HumacyteConference / presentation

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief

Related news

HUMAHumacyte2026-05-26 12:00 EST

Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access

HUMAHumacyte2026-07-14 12:00 EST

Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access

View all latest news

Humacyte

Bioengineered Human Tissue Platform Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale. SYMVESS SYMVESS is an FDA-approved acellular tissue-engineered...

Recent company news

HUMAHumacyte2026-09-10 12:00 EST

Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference

HUMAHumacyte2026-09-09 12:00 EST

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

HUMAHumacyte2026-08-24 12:00 EST

Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions

HUMAHumacyte2026-08-19 12:00 EST

Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results

HUMAHumacyte2026-08-18 12:00 EST

Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”

Stock data

Close
0.59 USD
Market cap
308.61M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States